Bibliographic details
Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Services Research 2014; 14(1): 419
MeSH
Adult; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2 /drug therapy /economics; Female; Glucagon-Like Peptide 1 /administration & Greece; Humans; Hypoglycemic Agents /administration & Liraglutide; Male; Middle Aged; Peptides /administration & Pyrazines /administration & Sitagliptin Phosphate; Triazoles /administration & Venoms /administration & derivatives /economics; dosage /analogs & dosage /economics; dosage /economics; dosage /economics; dosage /economics; dosage /economics